Oncology & Cancer

Two therapeutic targets identified for deadly lung cancer

The vast majority of deadly lung cancer cases (85 percent) are termed non-small-cell lung carcinomas (NSCLCs), which often contain a mutated gene called LKB1. Salk Institute researchers have now discovered precisely why inactive ...

Oncology & Cancer

A new way to stop cancer cells from killing their healthy neighbors

One of the reasons cancer cells are so robust against the body's natural defenses is that they are in fact human cells, and as such they have the innate machinery not only to trick the body's defense and maintenance systems, ...

Oncology & Cancer

Unlocking therapies for hard-to-treat lung cancers

Now, a new Salk Institute study, published on July 24, 2019, in the journal Science Advances, shows that researchers could target these hard-to-treat cancers by pursuing drugs that keep a cellular "switch," called CREB, from ...

Oncology & Cancer

Genome screen uncovers new targets for cancer immunotherapy

Immunotherapy has revolutionized the treatment of cancer in the last decade, yet many tumors do not respond to these new therapies. A new genome-wide screen of 20,000 human genes in T cells have turned up several new candidates ...

page 1 from 2